Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill

Page standards status: Informative

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="7750"/>
  <meta>
    <versionId value="9"/>
    <lastUpdated value="2026-08-24T14:28:27.896Z"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml">
  <table class="narrative-table">
    <tbody>
<tr>


<th colspan="2" scope="row" class="row-header"><a name="metadata"> </a>Metadata</th>


</tr>















  
<tr>


<th scope="row" class="row-header">Identifier</th>



<td class="content-container">7750</td>


</tr>





























<tr>


<th scope="row" class="row-header">Steward (Publisher)</th>



<td class="content-container">Computable Publishing LLC</td>


</tr>











<tr>


<th scope="row" class="row-header">Description</th>



<td class="content-container"><div><p>An enumerated group participating in a randomized trial.</p>
</div></td>


</tr>



<tr>


<th scope="row" class="row-header">Copyright</th>



<td class="content-container"><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div></td>


</tr>











<tr>


<th scope="row" class="row-header">Type</th>



<td class="content-container">Person</td>


</tr>








<tr>


<th scope="row" class="row-header">Quantity</th>



<td class="content-container">2244</td>


</tr>
























































<tr>
  <th colspan="2" scope="row" class="row-header">Generated using version 0.5.6 of the sample-content-ig Liquid templates</th>
</tr>

    </tbody>
  </table>
</div>
  </text>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
    <valueCodeableConcept>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
        <code value="active"/>
        <display value="Active"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Brian S. Alper"/>
    </valueContactDetail>
  </extension>
  <extension url="http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as">
    <valueMarkdown
                   value="Participants in Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT (hospitalized, not critically ill) [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 7750. Revised 2022-01-11. Available at: https://fevir.net/resources/Group/7750. Computable resource at: https://fevir.net/resources/Group/7750#json."/>
  </extension>
  <url value="https://fevir.net/resources/Group/7750"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net/FOI"/>
    <value value="7750"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <name
        value="Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill"/>
  <status value="active"/>
  <date value="2022-01-11T17:20:56.687Z"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="An enumerated group participating in a randomized trial."/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <type value="person"/>
  <membership value="enumerated"/>
  <quantity value="2244"/>
  <combinationMethod value="all-of"/>
  <characteristic>
    <code>
      <text value="Research Study for which this is the observed sample"/>
    </code>
    <valueReference>🔗 
      <reference value="PublicationRecord/7636"/>
      <display
               value="Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Journal Article]. Contributors: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. In: The New England Journal of Medicine, DOI 10.1056/NEJMoa2105911. Published August 04, 2021. Available at: https://doi.org/10.1056/NEJMoa2105911."/>
    </valueReference>
    <exclude value="false"/>
    <description
                 value="Participant in the Anticoagulation for COVID-19 Combined (ATTACC, ACTIV-4a, and REMAP-CAP) RCT"/>
  </characteristic>
  <characteristic>
    <code>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="305335007"/>
        <display value="Admission to establishment (procedure)"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="32485007"/>
        <display value="Hospital admission"/>
      </coding>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="Hospitalized"/>
  </characteristic>
  <characteristic>
    <code>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="64572001"/>
        <display value="Disease (disorder)"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="840539006"/>
        <display
                 value="Disease caused by severe acute respiratory syndrome coronavirus 2 (disorder)"/>
      </coding>
      <text
            value="ATTACC and ACTIV-4a limited inclusion to patients with confirmed COVID-19 (and excluded initially entered participants who did not have confirmed SARS-CoV-2. REMAP-CAP however included patients with confirmed COVID-19 or suspected COVID-19 with intent to test for COVID-19."/>
    </valueCodeableConcept>
    <exclude value="false"/>
    <description value="COVID-19"/>
  </characteristic>
  <characteristic>
    <code>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="246112005"/>
        <display value="Severity"/>
      </coding>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="http://snomed.info/sct"/>
        <code value="442452003"/>
        <display value="Life threatening severity"/>
      </coding>
      <text
            value="severe disease defined as ICU-level care or critically ill where ICU-level care was defined as the use of respiratory or cardiovascular organ support (oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes)"/>
    </valueCodeableConcept>
    <exclude value="true"/>
    <description value="not critically ill"/>
  </characteristic>
</Group>